The choice between p53-induced senescence and quiescence is





































Depending on the cell type and other factors p53 
activation can result in apoptosis, reversible 
(quiescence) and irreversible (senescence) cell cycle 
arrest [1-8]. While the choice between apoptosis and 
cell cycle arrest has been intensively scrutinized, the 
choice between quiescence and senescence was not 
systematically addressed and remains elusive.  In order 
to observe whether p53 activation causes either 
senescence or quiescence, others and we employed 
nutlin-3a. Nutlin-3a, a small molecular therapeutic, 
inhibits Mdm2/p53 interaction and induces p53 at 
physiological levels without causing DNA damage [9-
11]. It was reported that nutlin-3a caused senescent 
morphology and permanent loss of proliferative 
potential [12, 13].  However, in other cell lines nutlin-3a 
caused quiescence so that cells resumed proliferation, 





































recently reported that in human fibroblasts (WI-38tert) 
and fibrosarcoma cells (HT-1080-p21-9), in which 
nutlin-3a caused quiescence [16], p53 acted as a 
suppressor of senescence [17]. Thus, ectopic expression 
of p21 in these cells caused senescence, while 
simultaneous induction of p53 converted senescence 
into quiescence [17]. In agreement with previous reports 
[18-20], we found that p53 inhibited the mTOR 
pathway [17]. Importantly, the mTOR pathway is 
involved in cellular senescence [21-26]. We suggested 
that p53-mediated arrest remains reversible as long as 
p53 inhibits mTOR. If this model is correct, then 
senescence would occur in those cells, in which p53 is 
incapable of suppressing mTOR. Here we provide 
experimental evidence supporting this prediction and 
demonstrate that irreversibility of p53-mediated arrest 






















TSC2,  a  negative  regulator  of  mTOR,  partially  converted  quiescence  into  senescence  in  these  nutlin‐arrested  cells.  In
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Depletion of TSC2 favors senescence by p53   
 
We have shown that nutlin-3a caused quiescence in HT-
p21-9 cells and WI-38tert cells [16]. In these cells, 
nutlin-3a actively suppressed senescence and this 
suppression was associated with inhibition of the 
mTOR pathway by p53 [17].  Next, we investigated 
whether nutlin-3a can cause senescence in cells lacking  
tuberous sclerosis 2 (TSC2) (Figure 1A), given that 
regulation of mTOR by p53 requires TSC2 [18]. The 
transduced cells were transiently treated with nutlin-3a 
as shown (Figure 1B). The Tsc2-depleted cells acquired 
a large/flat morphology and could not resume 
proliferation, whereas cells treated with vector and 
nutlin-3a did not become senescent and resumed 
proliferation, forming colonies after removal of nutlin-
3a (Figure 1C-D). The potency of shTSC2 with 
different sequences varied and two other shTSC2 were 
less potent but still depleted TSC2 at some time points  
(Supplemental Figure 1) and partially decreased the 
proliferative potential in nutlin-3a-arrested cells 
(Supplemental Figure 1).  
 
We next extended this observation to WI-38tert cells 





























3a caused a lean morphology, a characteristic of 
quiescence [16]. Depletion of TSC2 by shTSC2 
converted quiescent morphology to senescent morpholo-
gy (Figure 2B).  Furthermore, this was associated with 
permanent loss of proliferative potential (Figure 2C). In 
control, cells resumed proliferation after removal of 
nutlin-3a, whereas nutlin-3a caused permanent loss of 
proliferative potential in shTSC2-treated cells (Figure 
2C). In agreement with our results, it was previously 
observed that knockout of Tsc2 cooperates with p53 in 
induction of cellular senescence in MEFs [27].  
 
Nutlin-3 causes senescence in Mel-10 and -9 cells  
 
We next wished to identify senescence-prone cells, 
which undergo senescence in response to nutlin-3a.  
In MEL-10 and Mel-9, two melanoma-derived cell 
lines, nutlin-3a induced p53 and p21 (Figure 3A) and 
caused senescent morphology (Figure 3B) and cells 
did not resume proliferation, when nutlin-3a was 
removed (Supplemental Figure 2). In contrast, 
rapamycin did not cause senescent morphology and 
cells resumed proliferation, when rapamycin was 
removed (Figure 3B and Supplemental Figure 2). 
Unlike rapamycin, nutlin-3a did not inhibit S6 
phosphorylation (Figure 3A), a marker of rapamycin-



























































































































































































Rapamycin suppresses nutlin-3a-induced senescence  
 
  To establish a causal link between mTOR and 
senescence, we next investigated whether inhibition of 
the mTOR pathway by rapamycin could convert nutlin-
3a-induced senescence into quiescence. Rapamycin did 
not affect p53 and p21 induction caused by nutlin-3a 
but abrogated S6 phosphorylation (Figure 4A), 
associated with conversion from senescent morphology 
to quiescent morphology (Figure 4B).  Importantly, 
cells were capable to resume proliferation following 
removal of nutlin-3a and rapamycin, indicating that the 
condition was reversible (Figure 4C). Similar results 
were obtained with Mel-9 cells (data not shown).  
 
Next, we extended this observation to cells of different 
tissue and species origin. As shown previously, nutlin-
3a caused senescence in mouse embryonic fibroblasts 
(MEFs) [13]. Here we showed that nulin-3a failed to 
inhibit mTOR pathway in MEF (Figure 5A), and caused 
senescence (Figure 5 B). Rapamycin inhibited the 
mTOR pathway and converted senescent morphology to 
quiescent morphology (Figure 5). This suggests that 
failure to suppress a rapamycin-sensitive pathway 





The role of p53 in organismal aging and longevity is 
complex [28-32], indicating that p53 may act as anti-






































































www.impactaging.com                   347                                             AGING,    June 2010, Vol.2 No.6monstrated that p53 can suppress cellular senescence, 
converting it into quiescence [17]. In these quiescence-
prone cells, p53 inhibited the mTOR pathway, which is 
involved in senescence program (Figure 6A). Still p53 
induces senescence in numerous cell types. Here we 
showed that in those cell types, in which nutlin-3a 
caused senescence, it failed to inhibit the mTOR 
pathway (Figure 6B). The role of active mTOR as a 
senescence-inducing factor in these cells was 
demonstrated by using rapamycin, which partially 
converted nutlin-3a-induced senescence into quiescence 
(Figure 6B, lower panel). This indicates that rapamycin-
sensitive mTOR activity is necessary for senescence 
during nutlin-3a-induced cell cycle arrest. And vice 
versa, in quiescence-prone cells, depletion of TSC2 
converted quiescence into senescence (Figure 6A, lower 






































the mTOR pathway favors senescence (Figure 7). In 
agreement, Ras accelerated senescence in nutlin-
arrested cells [13]. Similarly, activation of Ras and 
MEK in murine fibroblasts converted p53-induced 
quiescence into senescence [33]. Interestingly, p53 
levels did not correlate with the senescence phenotype, 
suggesting that factors other than p53 may determine 
senescence [33]. These important observations are in 
agreement with our model that senescence requires two 
factors: cell cycle arrest caused by p53 and simul-
taneous activation of the growth-promoting mTOR 
pathway (Note: Ras is an activator of the mTOR 
pathway). And vice versa it was observed that induction 
of p53 maintains quiescence upon serum starvation, 
without causing senescence [34]. In agreement, our 
model predicts that, by deactivating mTOR, serum 







































Figure  6.  p53  causes  senescence  by  failing  to  suppress  senescence.  (A)




pathway,  thus  ensuring  senescence.  Lower  panel.  Rapamycin  inhibits  mTOR  thus
converting senescence into quiescence 
   















Another factor that favors senescence is the duration of 
cell cycle arrest [13, 35]. Importantly, the duration of 
the arrest may exceed the duration of treatment with 
nutlin-3a because of persistent induction of p21 even 
after removal of nutlin-3a in some cancer cell lines [35]. 
Additional pathways may be involved in the senescence 
program. For example, nutlin-3a induces cytoskeletal 
rearrangement [36]. We speculate that p53 affects not 
only rapamycin-sensitive mTORC1 but also the 
mTORC2 complex, given that mTORC2 controls the 
actin cytoskeleton [37]. Also, p53 inhibits downstream 
branches of the mTOR pathway [38, 39]. P53 stimulates 
autophagy [18, 40], which in turn is essential for life-
extension by pharmacological manipulations (see [41-
44]). Finally, p53 affects cellular metabolism [45-48] 
and this effect may contribute to suppression of cellular 
senescence and synergistically potentate metabolic 
changes caused by mTOR inhibition. The relative 
contribution of all these mutually dependent factors 
needs further investigations. The key role of mTOR in 
cellular senescence links cellular and organismal aging 
and age-related diseases. 
 
MATERIAL AND METHODS 
 
Cell lines and reagents. HT-p21-9 cells are derivatives 
of HT1080 human fibrosarcoma cells, where p21 
expression can be turned on or off using a 
physiologically neutral agent isopropyl--thio-
galactosidase (IPTG) [16, 49-51]. HT-p21-9 cells 
express GFP.  WI-38-Tert, WI-38 fibroblasts 
immortalized by telomerase were described previously 
[16, 17]. Melanoma cell lines, MEL-9 (SK-Mel-103) 
and MEL-10 (SK-Mel-147), were described previously 
[52, 53].  RPE cells were described previously [21, 22]. 
MEF, mouse fibroblasts isolated from 13-day embryos, 
were provided by Marina Antoch (RPCI) and 
maintained in DMEM supplemented with 10% FCS. 

















Aldrich, St. Louis, MO), nutlin-3a (Sigma-Aldrich) 
were used as previously described [17].  
 
Lentiviral shRNA construction. Bacterial glycerol 
stocks [clone NM_000548.2-1437s1c1 (#10), 
NM_000548.x-4581s1c1 (#7) and NM_000548.2-
4551s1c1 (#9)] containing lentivirus plasmid vector 
pLKO.1-puro with shRNA specific for TSC2 was 
purchased from Sigma. The targeting sequences are: 
CCGGGCTCATCAACAGGCAGTTCTACTCGAGTA
GAACTGCCTGTTGATGAGCTTTTTG (#10), CCGG 
CAATGAGTCACAGTCCTTTGACTCGAGTCAAAG
GACTGTGACTCATTGTTTTTG (#7) and  CCGGCG 
ACGAGTCAAACAAGCCAATCTCGAGATTGGCTT
GTTTGACTCGTCGTTTTTG (#9).   
 
pLKO.1-puro lentiviral vector without shRNA was 
used as a control. Lentiviruses were produced in 
HEK293T cells after co-transfection of lentivirus 
plasmid vector with shRNA or control vector with 
packaging plasmids using Lipofectamine2000 
(Invitrogen). After 48h and 72h medium containing 
lentivirus was collected, centrifuged at 2000g and 
filtered through 0.22 uM filter. Filtered virus 
containing medium was used for cell infection or 
stored at -80 C. Cells were transduced with lentivirus 
in the presence of 8 mg/ml polybrene and selected 
with puromycin (1-2 mg/ml) for 4-6 days. Cells were 
treated with drugs either 24h after transduction or after 
puromycin selection for infected cells. 
 
Colony formation assay. Plates were fixed and stained 
with 1.0 % crystal violet (Sigma-Aldrich).   
 
Immunoblot analysis. The following antibodies were 
used: anti-p53 and anti-p21 antibodies from Cell 
signaling and anti-actin antibodies from Santa Cruz 
Biotechnology,  rabbit anti-phospho-S6 (Ser240/244) 
and (Ser235/236), mouse anti-S6, mouse anti-phospho- 
Figure 7. Activation of the mTOR pathway favors senescence in nutlin‐3a‐arrested cells 
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phospho-4E-BP1 (Thr37/46) from Cell Signaling; 
mouse anti-4E-BP1 from Invitrogen; mouse anti-p53 
(Ab-6) from Calbiochem. 
 
Beta-galactosidase staining. beta-Gal staining was 
performed using Senescence -galactosidase staining kit 
(Cell Signaling Technology) according to 
manufacturer’s protocol. 
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Supplemental  Figure  1.  Depletion  of  TSC2  converts
quiescence into senescence in HT‐p21‐9 cells. (A) HT‐p21‐9 
cells were transduced with control lentivirus (pLKO) or lentivirus
expressing  shTSC2  (sequence  #  7,  8,  9)  and  selected  with
puromycin for 10 days and then immunoblot was performed. (B)




were  cultivated  in  fresh  medium  for  8  days.  Colonies  were
stained with crystal violet. 
Supplemental Figure 2. Irreversible and reversible effects of
nutlin‐3a and rapamycin:  Mel‐10 and Mel‐9 cells were incubated
with 10 uM nutlin (N) and 500 nM rapamycin (R) for 4 day and
then nutlin‐3a was washed. After a week, cells were counted. 